- Home
- OPK
OPK
OPKO Health Inc.
as 08-22-2025 4:00pm EST
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 1.0B | IPO Year: | 1995 |
| Target Price: | $2.75 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $2.04 | Next Earning Date: | 07-31-2025 |
| Revenue: | $664,029,000 | Revenue Growth: | -7.31% |
| Revenue Growth (this year): | -8.01% | Revenue Growth (next year): | 6.98% |
Latest OPKO Health Inc. News
OPK Breaking Stock News: Dive into OPK Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
GlobeNewswire
2 months ago
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
GlobeNewswire
2 months ago
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Insider Monkey
2 months ago
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
Zacks
2 months ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
GlobeNewswire
2 months ago
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Simply Wall St.
3 months ago
Strong week for OPKO Health (NASDAQ:OPK) shareholders doesn't alleviate pain of three-year loss
GlobeNewswire
3 months ago
OPKO Health to Participate in Two Upcoming Investor Conferences
Compare OPK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPK OPKO Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.